Niche market focus Target the pruritus and prurigo nodularis space in end-stage renal disease patients, presenting a clear specialized patient population for dermatology and nephrology collaborations, payer discussions, and KOL engagement.

First mover advantage Position AV104 as the only once-daily non-invasive oral transmucosal therapy in this niche, which can enable talking points around fast onset, high bioavailability, reduced liver metabolism, and lower excretory burden for CKD patients.

Early funding signals Leverage recent pre-Series A financing and NIH non-dilutive grant history to support co-development, grant-backed trials, and potential non-dilutive partnerships with academic medical centers and contract research organizations.

Small but nimble With a lean team, emphasize agile collaboration opportunities with CROs, biotech partners, and specialty pharmacies to accelerate clinical milestones, regulatory planning, and market access strategies.

Strategic collaborations Propose partnerships with nephrology clinics, dermatology networks, NKF-affiliated groups, and payer pilots to validate real-world outcomes, support value-based pricing, and build a compelling case for insurance coverage and reimbursement.